Department of Pediatrics, University of Washington, Seattle.
American Academy of Pediatrics, Itasca, Illinois.
JAMA Pediatr. 2022 Jan 1;176(1):26-33. doi: 10.1001/jamapediatrics.2021.4267.
Given that hypotonic maintenance intravenous fluids (IVF) may cause hospital-acquired harm, in November 2018, the American Academy of Pediatrics released a clinical practice guideline recommending the use of isotonic IVF for patients aged 28 days to 18 years without contraindications. No recommendations were made regarding laboratory monitoring; however, unnecessary laboratory tests may contribute to health care waste and harm patients.
To examine the effect of a quality improvement intervention bundle on (1) increasing the mean proportion of hours per hospital day with exclusive isotonic IVF use to at least 80% and (2) decreasing the mean proportion of hospital days with laboratory tests obtained.
DESIGN, SETTING, AND PARTICIPANTS: This stepped-wedge, cluster randomized clinical trial (Standardization of Fluids in Inpatient Settings [SOFI]) was sponsored by a national quality improvement collaborative and was conducted across 106 US pediatric hospitals. The SOFI intervention period was from September 2019 to March 2020.
Hospital sites were exposed to educational materials, a clinical algorithm and order set for IVF use, electronic medical record interventions to reduce laboratory testing, and "harms of overtesting" cards.
Primary outcomes were mean proportion of hours per hospital day receiving exclusive isotonic IVF and mean proportion of hospital days with laboratory test values obtained. Secondary measures included total IVF duration per hospital day, daily patient weight measurement while receiving IVF, serum sodium testing, and adverse events. Baseline data were collected for 2 months; intervention period data, 7 months. Outcomes were analyzed using linear mixed-effects regression models.
A total of 106 hospitals were randomly assigned to 1 of 3 intervention start dates (wedges), and 100 hospitals (94%) completed the study. In total, 5215 hospitalizations were reviewed before the intervention, and 6724 hospitalizations were reviewed after the intervention. Prior to interventions, the mean (SD) proportion of hours per day with exclusive isotonic IVF use was 88.5% (31.7%). Interventions led to an absolute increase of 5.4% (95% CI, 3.9%-6.9%) above baseline in exclusive isotonic IVF use but did not change the proportion of hospital days during which a laboratory test value was obtained (estimated difference, 0.1%; 95% CI, -1.5% to 1.7%; P = .90), IVF use duration (estimated difference, -1.2%; 95% CI, -2.9% to 0.4%), serum sodium testing, or adverse events. There was an absolute increase of 4.4% (95% CI, 2.6%-6.2%) in the mean proportion of hospital days with a patient weight measurement while receiving IVF.
In this stepped-wedge, cluster randomized clinical trial, an intervention bundle significantly improved the use of isotonic maintenance IVF without a concomitant increase in adverse events or electrolyte testing. Further work is required to deimplement laboratory testing.
ClinicalTrials.gov Identifier: NCT03924674.
鉴于低张维持静脉输液(IVF)可能导致医院获得性伤害,2018 年 11 月,美国儿科学会发布了一份临床实践指南,建议在没有禁忌症的情况下,为 28 天至 18 岁的患者使用等张 IVF。对于实验室监测,没有提出建议;然而,不必要的实验室测试可能会导致医疗保健浪费并伤害患者。
检查质量改进干预包对(1)增加每个医院日使用等张 IVF 的时间比例至少达到 80%,(2)减少有实验室测试值的医院日比例的影响。
设计、地点和参与者:这是一项分层楔形、集群随机临床试验(住院患者液体标准化研究[SOFI]),由国家质量改进合作组织赞助,在美国 106 家儿科医院进行。SOFI 干预期为 2019 年 9 月至 2020 年 3 月。
医院接受了教育材料、IVF 使用的临床算法和医嘱集、减少实验室测试的电子病历干预措施以及“过度测试的危害”卡片。
主要结果是每个医院日接受等张 IVF 的时间比例和有实验室测试值的医院日比例。次要措施包括每天 IVF 持续时间、接受 IVF 时的患者体重测量、血清钠测试和不良事件。在干预前收集了 2 个月的基线数据;干预期间收集了 7 个月的数据。使用线性混合效应回归模型分析结果。
共有 106 家医院被随机分配到 3 个干预开始日期(楔形)中的 1 个,其中 100 家(94%)完成了研究。总共审查了 5215 例住院治疗,干预后审查了 6724 例住院治疗。在干预之前,每天使用等张 IVF 的时间比例的平均值(SD)为 88.5%(31.7%)。干预导致每天使用等张 IVF 的时间比例绝对增加了 5.4%(95%置信区间,3.9%-6.9%),但没有改变获得实验室测试值的医院日比例(估计差异,0.1%;95%置信区间,-1.5%至 1.7%;P = .90)、IVF 使用持续时间(估计差异,-1.2%;95%置信区间,-2.9%至 0.4%)、血清钠测试或不良事件。接受 IVF 时患者体重测量的平均医院日比例绝对增加了 4.4%(95%置信区间,2.6%-6.2%)。
在这项分层楔形、集群随机临床试验中,干预包显著改善了等张维持 IVF 的使用,而没有增加不良事件或电解质测试。需要进一步努力来减少实验室测试。
ClinicalTrials.gov 标识符:NCT03924674。